Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading activity on Thursday. Investors purchased 23,699 call options on the stock. This is an increase of 51% compared to the typical volume of 15,658 call options.

Insider Activity

In related news, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the transaction, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. GAMMA Investing LLC boosted its holdings in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on RXRX. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday.

Recursion Pharmaceuticals Price Performance

RXRX opened at $7.24 on Friday. The firm has a market cap of $2.83 billion, a price-to-earnings ratio of -4.73 and a beta of 0.86. Recursion Pharmaceuticals has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The company’s 50-day moving average price is $7.14 and its 200 day moving average price is $6.91. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter last year, the company posted ($0.43) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% on a year-over-year basis. As a group, sell-side analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.